Disease: Parkinson's disease
Type of study: Interventional trial
Coordinating investigator: Brage Brakedal
Study director: Charalampos Tzoulis
Background: We are conducting a phase-II, double-blinded randomised clinical trial of oral nicotinamide riboside (NR) in early Parkinson’s disease (PD) (see the NOPARK study). To evaluate the long-term safety of NR in PD, and to offer participants the opportunity to benefit from potential neuroprotective effects, we are conducting an open label extension study offering to enrol all participants who completed the NOPARK trial.
The primary objective of the NOPARK extension study is to assess the safety profile of long-term treatment with oral NR.
Design: The NOPARK extension study is a phase II open label clinical trial of oral NR, 1200 mg per day, in PD. The NOPARK extension study is recruiting participants who have completed the NOPARK study, from 10 centres across Norway.
Primary endpoint: The frequency of reported adverse events (AE) among all participants in the NOPARK open label extension.
Status: The study is fully enrolled and will be concluded in June 2025.
Participating centres
- Haukeland University Hospital, Bergen
- Akershus University Hospital, Lørenskog
- Oslo University Hospital, Oslo
- Vestre Viken Hospital, Drammen
- Østfold Hospital, Kalnes
- Nordland Hospital, Bodø
- University Hospital of North Norway, Tromsø
- Førde Hospital, Førde
- Dr. Karen Herlofson, Arendal
- Sørlandet Hospital Arendal
- Haugesund Hospital, Haugesund
- Molde Hospital, Molde
Funding
- KLINBEFORSK
- The Regional Health Authority of Western Norway
- The Research Council of Norway, Neuro-SysMed
- Haukeland University Hospital
- Participating hospitals